BioNTech (NASDAQ:BNTX) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research note released on Monday, Benzinga reports. They currently have a $113.00 price target on the stock.

Other analysts also recently issued research reports about the company. HSBC upgraded BioNTech from a hold rating to a buy rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. upgraded BioNTech from an underweight rating to a neutral rating and upped their target price for the company from $91.00 to $125.00 in a report on Monday. Hsbc Global Res raised shares of BioNTech from a hold rating to a strong-buy rating in a research report on Friday, August 2nd. Jefferies Financial Group upped their price target on BioNTech from $90.00 to $96.00 and gave the stock a hold rating in a research note on Friday, September 13th. Finally, TD Cowen decreased their target price on shares of BioNTech from $98.00 to $85.00 and set a hold rating for the company in a research note on Tuesday, August 6th. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, BioNTech currently has a consensus rating of Moderate Buy and a consensus target price of $120.31.

BioNTech Stock Down 7.3 %

Shares of NASDAQ BNTX opened at $115.62 on Monday. The business has a 50-day simple moving average of $89.02 and a two-hundred day simple moving average of $90.14. The company has a market cap of $27.49 billion, a P/E ratio of 231.24 and a beta of 0.23. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same quarter in the prior year, the company earned ($0.86) earnings per share. BioNTech’s revenue was down 23.3% compared to the same quarter last year. Research analysts anticipate that BioNTech will post -2.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in shares of BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after buying an additional 150 shares during the last quarter. Frazier Financial Advisors LLC purchased a new stake in BioNTech in the 4th quarter worth $30,000. Covestor Ltd raised its stake in BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the last quarter. Finally, Crewe Advisors LLC bought a new stake in BioNTech in the 1st quarter valued at $75,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.